People · Operator
Named in public records as an officer, director or promoter · active 2015–2017 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Codiak BioSciences, Inc. | — | Biotechnology | Series C | $107.5M | $3.1B | 2015 |
| Neon Therapeutics, Inc. | — | Biotechnology | Series D+ | $106.0M | $4.4B | 2016 |
Eric Lander at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Eric Lander on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Steven Gillis | 1 | 23 |
| Noubar Afeyan | 1 | 9 |
| Robert Tepper | 1 | 7 |
| Doug Williams | 1 | 5 |
| Charles L. Cooney | 1 | 4 |
| Robert Kamen | 1 | 3 |
| Stephen Sherwin | 1 | 2 |
| Daniella Beckman | 1 | 2 |
| Richard Gaynor, M.D. | 1 | 1 |
| Cary Pfeffer, M.D. | 1 | 1 |
| Robert Ang, M.D. | 1 | 1 |
| Yasir Al-Wakeel | 1 | 1 |
| Hugh Dowd | 1 | 1 |
| Raghu Kalluri | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.